arrow
L

Leslie Cope

Johns Hopkins University
H指数:103
被引数:9.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

人类高级别浆液性卵巢癌的整合蛋白质基因组学特征

Cell
IF42.5
2025-11-040
PRE
Discovery of Methylated DNA Biomarkers for Potential Nonendoscopic Detection of Barrett's Esophagus and Esophageal Adenocarcinoma

甲基化DNA生物标志物的发现:用于Barrett's Esophagus和Esophageal Adenocarcinoma潜在的内镜外检测

2025-10-013
PRE
A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer

一项关于HPV16 L2E7E6融合蛋白疫苗接种后治疗HPV16+宫颈癌的随机试点研究

2025-08-200
PRE
Ossifying Spindled and Epithelioid Tumor: A Novel Soft Tissue Tumor

骨化性梭形细胞和上皮样肿瘤:一种新型软组织肿瘤

2025-07-160
PRE
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

癌症免疫治疗学会(SITC)关于免疫治疗临床方案关键生物标志物的共识声明

2025-03-071
OA
Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situ
2024-12-040
OAAI
Gene expression signatures in blood from a West African sepsis cohort define host response phenotypes
2024-05-300
OAAI
Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries
2024-04-202
OAAI
Immunomodulation of the tumor microenvironment of pancreatic ductal adenocarcinoma with histone deacetylase inhibition: Results of a phase 2 clinical trial of entinostat in combination with nivolumab
2024-04-051
PRE
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients

桂地他滨联合伊立替康与瑞戈非尼或TAS-102在伊立替康难治性转移性结直肠癌患者中的II期研究

2024-02-057
PRE
Multimodal genome-wide survey of progressing and non-progressing DCIS
2023-04-040
PRE